Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata lists "Biolife Solutions Inc," but the filing is for Cryomedical Sciences, Inc., which owns Biolife Solutions as a subsidiary).
Reporting Period: Quarterly period ended September 24, 2000 (13 weeks) and the 39 weeks ended September 24, 2000.
Business Overview: The Company engages in the research, development, marketing, and manufacture of low-temperature medicine products, primarily cryosurgical systems (AccuProbe series) and preservative solutions (Hypotermosol).
Key Financial Metrics
| Metric | 13 Weeks Ended Sep 24, 2000 | 39 Weeks Ended Sep 24, 2000 | 39 Weeks Ended Sep 26, 1999 |
|---|---|---|---|
| Revenues | $199,757 | $832,820 | $841,124 |
| Gross Profit | $79,077 (40% margin) | $444,560 (53% margin) | $296,977 (35% margin) |
| Net Loss | $(675,065) | $(1,682,801) | $(397,355) |
| Cash and Equivalents (End of Period) | $3,211,136 (as of Sep 24, 2000) | ||
| Working Capital | $3,691,266 (as of Sep 24, 2000) | ||
| Total Liabilities | $464,924 (as of Sep 24, 2000) |
Debt: The short-term credit facility balance was $0 as of September 24, 2000, down from $120,000 at year-end 1999. Capital leases totaled $17,351 ($14,623 current + $2,728 non-current).
Material Changes vs. Prior Period
- Revenue Decline: Revenue for the 13-week period dropped 56% to $199,757 from $450,294 in the prior year, attributed to a decline in the number of AccuProbe systems and accessories sold. The 39-week revenue remained relatively flat, down only 1%.
- Expense Surge: Operating expenses increased significantly. Research and Development (R&D) expenses rose 518% (13 weeks) and 753% (39 weeks) due to clinical trials for Hypotermosol solutions and increased raw material usage. General and Administrative expenses increased 122% and 141% respectively, driven by legal fees and personnel costs.
- Liquidity Improvement: Cash and cash equivalents increased from $7,952 at December 26, 1999, to $3,211,136 at September 24, 2000. This was primarily due to a private placement in May 2000 raising approximately $5.7 million.
- Profitability: The Company sustained a net loss of $1.68 million for the 39-week period, compared to $397,355 in the prior year, largely due to the spike in R&D and administrative costs.
Guidance, Outlook, and Risks
- Outlook: Management believes sales for the remainder of fiscal year 2000 may exceed prior year levels due to favorable reimbursement policies from HCFA regarding cryosurgery of the prostate. However, this depends on the ability to implement manufacturing protocols and increase marketing efforts.
- Capital Expenditures: The Company does not expect to spend more than $250,000 on equipment for the remainder of the year.
- Legal Contingency: A lawsuit filed by former VP Alan A. Rich resulted in a summary judgment awarding him $161,867.30. The Company settled this matter on September 5, 2000, agreeing to pay $155,000 to satisfy all claims.
- Risks: Forward-looking statements are subject to risks including market acceptance, regulatory conditions, and the receipt of future financing.
Investor Verification Checklist
- Revenue Sustainability: Verify the cause of the 56% revenue drop in the most recent quarter and whether the anticipated HCFA reimbursement benefits are materializing.
- R&D Burn Rate: Assess the timeline and expected return on the significant increase in R&D spending (up 753% YoY) for Hypotermosol clinical trials.
- Cash Runway: Confirm the remaining cash balance ($3.2M) is sufficient to cover the elevated operating losses and planned capital expenditures without further dilution.
- Legal Resolution: Confirm the $155,000 settlement payment has been recorded and that no further legal exposure remains from the Rich litigation.